See us at SIGGRAPH 2018!
Qi is honored to present at SIGGRAPH Next in Vancouver, BC on August 14.

About

Revolutionizing cancer research and paving the way for new treatments.



Quantitative Imaging Systems (Qi) is a biotechnology business founded in 2011 by Michel Nederlof, a physicist with over 30 years of experience in developing imaging systems, and a passion for unraveling cancer through digital imaging microscopy.

With decades of experience in microscope imaging technology, Qi software is designed with pitch-perfect domain knowledge of microscopy applications that provide solutions for biomedical research, drug development, and ultimately design of patient treatment plans. By combining next generation image analytics and visualization technologies, with recent advances in reagents and optics, Qi is breaking barriers in resolution, color, and dimensionality.

Tissue architectural information can now be augmented with highly multiplexed single cell analysis, providing a wealth of information that was previously not available. QiTissue combines the power of cell based analytics, machine learning, and visualization. This enables unprecedented insights into spatial concepts, such as tumor nests, islands of resistance, interactions with stroma during metastatic progression, and the effect of each type of immune cell.

What

Qi develops imaging software, takes part in large research projects, and builds entertaining apps, with the common goal to advance our knowledge of how cells work, what goes wrong in disease, and how to treat it!



Qi has received several grants related to the application of imaging technology to cancer research. These include creating a library of millions of phenotypic responses for the NIH LINCS project where cell lines are exposed to specific compounds in their microenvironments, and managing the Imaging Core for a new NCI Center for Cancer Systems Biology, providing image analytics for Measuring, Modeling and Controlling Heterogeneity.

Who

Who
Michel Nederlof, President and CEO
Michel Nederlof, PhD, is a physicist with 30+ years of experience in digital imaging microscopy for life sciences, ranging from fundamental technological developments, to advanced image analysis, drug development platforms and clinical applications. His academic career started at Max Planck Institute and Carnegie Mellon University. He continued to found six biotechnology companies that have created pioneering products in the areas of microscopy research, pharmaceutical drug discovery, and clinical diagnostics. They include Biological Detection Systems, which commercialized the Cyanine fluorescent dyes and created the MultiMode automated microscope, the first commercially available microscope with a cooled CCD camera. Cellomics pioneered High Content Screening (HCS) with groundbreaking systems, software and assays for the pharmaceutical industry. QED Imaging propelled digital camera technology into the field of biological research, and by integrating customized software and microscopy automation, created hundreds of the worlds most advanced microscopy systems. At Qi, he remains hands-on and oversees all technical developments on software as well as microscope and reagent integration.
Michel Nederlof, PhD, is a physicist with 30+ years of experience in digital imaging microscopy for life sciences, ranging from fundamental technological developments, to advanced image analysis, drug development platforms and clinical applications. His academic career started at Max Planck Institute and Carnegie Mellon University. He continued to found six biotechnology companies that have created pioneering products in the areas of microscopy research, pharmaceutical drug discovery, and clinical diagnostics. They include Biological Detection Systems, which commercialized the Cyanine fluorescent dyes and created the MultiMode automated microscope, the first commercially available microscope with a cooled CCD camera. Cellomics pioneered High Content Screening (HCS) with groundbreaking systems, software and assays for the pharmaceutical industry. QED Imaging propelled digital camera technology into the field of biological research, and by integrating customized software and microscopy automation, created hundreds of the worlds most advanced microscopy systems. At Qi, he remains hands-on and oversees all technical developments on software as well as microscope and reagent integration.
Who
Michel Nederlof, President and CEO
Who
Damir Sudar, Chief Science Officer
Damir Sudar, M.S. is the Chief Science Officer at Quantitative Imaging Systems, Inc. (Qi) and holds Visiting Scientist appointments at Oregon Health & Science University and at Lawrence Berkeley National Laboratory (LBNL). He graduated from the Delft University of Technology in the Netherlands where he received formal education in image analysis methodologies and did his graduate work on applications of microscopy and image analysis in biomedical research. Following post-doctoral work at the University of California in San Francisco, he continued research in biomedical applications of fluorescence microscopy and imaging at Lawrence Livermore National Laboratory and LBNL. He co-developed groundbreaking analytics for Fluorescence In-Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH). At LBNL he was instrumental in establishing a microscopy center, research in transcription regulation in complex organisms, and he moved into a leadership position as the deputy of the Life Sciences Division. During his career, he worked at Cellomics (now ThermoFisher) on high-content imaging and at a start-up on novel 3D imaging technology. He joined Qi in 2015 and develops automated microscopy techniques, image data processing and analysis software, and image data management systems. He is interested in integrating imaging modalities over multiple spatial, temporal, and functional/structural scales.
Damir Sudar, M.S. is the Chief Science Officer at Quantitative Imaging Systems, Inc. (Qi) and holds Visiting Scientist appointments at Oregon Health & Science University and at Lawrence Berkeley National Laboratory (LBNL). He graduated from the Delft University of Technology in the Netherlands where he received formal education in image analysis methodologies and did his graduate work on applications of microscopy and image analysis in biomedical research. Following post-doctoral work at the University of California in San Francisco, he continued research in biomedical applications of fluorescence microscopy and imaging at Lawrence Livermore National Laboratory and LBNL. He co-developed groundbreaking analytics for Fluorescence In-Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH). At LBNL he was instrumental in establishing a microscopy center, research in transcription regulation in complex organisms, and he moved into a leadership position as the deputy of the Life Sciences Division. During his career, he worked at Cellomics (now ThermoFisher) on high-content imaging and at a start-up on novel 3D imaging technology. He joined Qi in 2015 and develops automated microscopy techniques, image data processing and analysis software, and image data management systems. He is interested in integrating imaging modalities over multiple spatial, temporal, and functional/structural scales.
Who
Damir Sudar, Chief Science Officer
Who
Daniel Szecket, VP of Design
Daniel Szecket has been in the graphics industry since 1990, starting at Alias Research in Toronto using 3D custom software for Industrial Design and visual effects. From learning and teaching software around the world, he moved on to using it to create animated characters at Disney and Dreamworks. After a few years of studio work, he started a design consultancy making interactive storytelling technologies - Magritte’s Cow. He then moved over to real-time hardware content creation for ATI, working on demos to show off the cutting edge of graphics hardware. From there he went on to 10 years as a Designer at a design consultancy in Pittsburgh, designing processes, visuals, and experiences through rapid iteration and inquiry using Human Centered Design.
Daniel Szecket has been in the graphics industry since 1990, starting at Alias Research in Toronto using 3D custom software for Industrial Design and visual effects. From learning and teaching software around the world, he moved on to using it to create animated characters at Disney and Dreamworks. After a few years of studio work, he started a design consultancy making interactive storytelling technologies - Magritte’s Cow. He then moved over to real-time hardware content creation for ATI, working on demos to show off the cutting edge of graphics hardware. From there he went on to 10 years as a Designer at a design consultancy in Pittsburgh, designing processes, visuals, and experiences through rapid iteration and inquiry using Human Centered Design.
Who
Daniel Szecket, VP of Design
Who
COO of Qi BioSciences
Joseph has a background in commercializing and translating genomic technologies in various disease settings. Over his 15yr career initiating and managing research efforts in biopharma and biotech (with companies such as Genetics Institute (acq by Wyeth), Wyeth (acq by Pfizer) and Millennium Pharmaceuticals), he has worked to utilize genomics to improve drug development and clinical trial design. In 2004, Joseph co- founded Skinetics Biosciences, Inc.with a researcher at Columbia University and then moved to oversee research at Sirna Therapeutics (acq by Merck) after its acquisition of Skinetics. After leaving Sirna, Joseph moved back to the academic sector (Univ of Colorado (Boulder, CO), Biomedical Diagnostics Inst (Dublin, Ireland)) to work on facilitating greater academic-industry partnership and new venture creation. Most recently, Joseph oversaw business development and strategic alliances for the Knight Cancer Institute at OHSU where he established numerous corporate alliances for OHSU’s cancer researchers.
Joseph has a background in commercializing and translating genomic technologies in various disease settings. Over his 15yr career initiating and managing research efforts in biopharma and biotech (with companies such as Genetics Institute (acq by Wyeth), Wyeth (acq by Pfizer) and Millennium Pharmaceuticals), he has worked to utilize genomics to improve drug development and clinical trial design. In 2004, Joseph co- founded Skinetics Biosciences, Inc.with a researcher at Columbia University and then moved to oversee research at Sirna Therapeutics (acq by Merck) after its acquisition of Skinetics. After leaving Sirna, Joseph moved back to the academic sector (Univ of Colorado (Boulder, CO), Biomedical Diagnostics Inst (Dublin, Ireland)) to work on facilitating greater academic-industry partnership and new venture creation. Most recently, Joseph oversaw business development and strategic alliances for the Knight Cancer Institute at OHSU where he established numerous corporate alliances for OHSU’s cancer researchers.
Who
COO of Qi BioSciences

Contact

We welcome requests for collaborations, early adopters of our technology, or talented individuals to become part of our team.